Use of real‐world data and evidence in drug development of medicinal products centrally authorized in Europe in 2018–2019
SM Eskola, HGM Leufkens, A Bate… - Clinical …, 2022 - Wiley Online Library
Real‐world data/real‐world evidence (RWD/RWE) are considered to have a great potential
to complement, in some cases, replace the evidence generated through randomized …
to complement, in some cases, replace the evidence generated through randomized …
Use of Real‐World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018–2019.
SM Eskola, HGM Leufkens, A Bate… - Clinical …, 2022 - search.ebscohost.com
Real‐world data/real‐world evidence (RWD/RWE) are considered to have a great potential
to complement, in some cases, replace the evidence generated through randomized …
to complement, in some cases, replace the evidence generated through randomized …
[PDF][PDF] Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018–2019
SM Eskola, HGM Leufkens, A Bate, ML De Bruin… - researchgate.net
METHODS For this study, a cohort of medicinal products, except generics and biosimilars,
centrally authorized in Europe from January 1, 2018, until December 31, 2019 (n= 111) was …
centrally authorized in Europe from January 1, 2018, until December 31, 2019 (n= 111) was …
Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019.
SM Eskola, HGM Leufkens, A Bate… - Clinical …, 2021 - europepmc.org
Real‐world data/real‐world evidence (RWD/RWE) are considered to have a great potential
to complement, in some cases, replace the evidence generated through randomized …
to complement, in some cases, replace the evidence generated through randomized …
[PDF][PDF] Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018–2019
SM Eskola, HGM Leufkens, A Bate, ML De Bruin… - CLINICAL …, 2022 - hnrws.cn
METHODS For this study, a cohort of medicinal products, except generics and biosimilars,
centrally authorized in Europe from January 1, 2018, until December 31, 2019 (n= 111) was …
centrally authorized in Europe from January 1, 2018, until December 31, 2019 (n= 111) was …
[PDF][PDF] Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018–2019
SM Eskola, HGM Leufkens, A Bate, ML De Bruin… - CLINICAL …, 2022 - hnrws.cn
METHODS For this study, a cohort of medicinal products, except generics and biosimilars,
centrally authorized in Europe from January 1, 2018, until December 31, 2019 (n= 111) was …
centrally authorized in Europe from January 1, 2018, until December 31, 2019 (n= 111) was …
[HTML][HTML] Use of Real‐World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018–2019
SM Eskola, HGM Leufkens, A Bate… - Clinical …, 2022 - ncbi.nlm.nih.gov
Real‐world data/real‐world evidence (RWD/RWE) are considered to have a great potential
to complement, in some cases, replace the evidence generated through randomized …
to complement, in some cases, replace the evidence generated through randomized …
Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019
SM Eskola, HGM Leufkens, A Bate… - Clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
Real-world data/real-world evidence (RWD/RWE) are considered to have a great potential
to complement, in some cases, replace the evidence generated through randomized …
to complement, in some cases, replace the evidence generated through randomized …